Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

European Regulators: Brexit's Effect On FDA Inspection Pact With EU Unclear

August 5, 2016, FDA Week

Grant Castle is quoted in an FDA Week article regarding the likelihood that the UK will remain part of the Mutual Reliance Initiative between the U.S. and EU. "If the UK does Brexit, but executes the European Economic Area (EEA) Agreement, as Norway, Iceland and Liechtenstein have done, it would continue to implement all new EU pharmaceutical rules and participate in the EU pharmaceutical regime." He continues, “Whatever the outcome of a Brexit, we can be pretty sure that the UK would continue to operate and inspect against standards of GMP that are recognised [sic] globally, which would most likely be EU GMPs.”

Share this article: